



EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

August 2, 2022

WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals' will present at the following upcoming conferences:

- **BTIG Biotechnology Conference**

Forum: Panel

Date: Tuesday, August 9, 2022

Time: 10:00 a.m. ET

- **H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference**

Forum: Corporate Presentation / Panel

Date: Wednesday, August 17, 2022

Time: 7:00 a.m. ET / 11:00 a.m. ET

A webcast and subsequent archived replay of the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference corporate presentation and panel may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event. The live webcast of the BTIG panel will be available on BTIG's conference website at the time of the event, and a replay will be available through BTIG's research access.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia

Stern IR

Direct: 212-698-8700

christina.tartaglia@sternir.com

Media Contact

Amy Phillips

Green Room Communications

Direct: 412-327-9499

aphillips@greenroompr.com



Source: EyePoint Pharmaceuticals, Inc.